Controversies in T-Cell Lymphoma

In a compelling expert panel session held during the 2^nd Annual HemOnc Pulse Live!, leading hematologic oncologists tackle the most pressing unanswered questions in T-cell lymphoma research and clinical practice. The discussion is led by Timothy Fenske, MD, medical director, Immune Effector Cell Therapy. Sarah Cannon Transplant & Cellular Therapy program, Methodist Hospital in San Antonio, TX.

Panelists:

• Jasmine M. Zain, MD, Memorial Sloan Kettering Cancer Center
• Alejandro Sica, MD, Montefiore Medical Center
• Swaminathan P. Iyer, MD, The University of Texas MD Anderson Cancer Center
• Mohamed A. Kharfan Dabaja, MD, MBA, Mayo Clinic

The panel discuses real-world cases and evolving treatment strategies. They explore the limitations of standard CHOP-based regimens, the emerging role of targeted therapies like ruxolitinib and venetoclax, and the integration of antiviral treatments such as Biktarvy in HTLV-1 associated adult T-cell leukemia/lymphoma. The panelists stress the need for early allogeneic transplant, especially in first complete remission, and discuss the bimodal age distribution of patients.

The conversation also covers the role of next-generation sequencing (NGS) in shaping clinical decisions, especially in relapsed settings. While acknowledging the lack of standardized guidelines, the experts reflect on the growing use of NGS panels to identify targetable mutations and guide personalized therapies.